Pasar al contenido principal

ESTUDIO DE LA FUNCION MITOCONDRIAL, LA AUTOFAGIA Y LA MITOFAGIA EN LA DIABETES TIPO 2: RELACION CON LAS COMPLICACIONES CARDIOVASCULARES E IMPLICACIONES CLINICAS

PI19/00838

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA EL FOMENTO DE LA INV. SANITARIA Y BIOMEDICA DE LA COMUNIDAD VALENCIANA (FISABIO)
Centro realización HOSPITAL DOCTOR PESET

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Hypoxia Increases Nitric Oxide-Dependent Inhibition of Angiogenic Growth

  • Arce, Cristina
  • Vicente, Diana
  • Monto, Fermí
  • González, Laura
  • Nuñez, Cristina
  • Victor, Victor Manuel|||0000-0002-3027-3945
  • Jiménez Altayó, Francesc|||0000-0002-9034-2041
  • D'Ocon, Pilar|||0000-0001-8544-7124
Nitric oxide (NO) is a proangiogenic factor acting through the soluble guanylate cyclase (sGC) pathway. However, angiogenic growth increases energy demand, which may be hampered by NO inhibition of cytochrome c oxidase (CcO). Then, NO activity would be the balanced result of sGC activation (pro-angiogenic) and CcO inhibition (anti-angiogenic). NO activity in a rat and eNOS mice aortic ring angiogenic model and in a tube formation assay (human aortic endothelial cells) were analyzed in parallel with mitochondrial O consumption. Studies were performed with NO donor (DETA-NO), sGC inhibitor (ODQ), and NOS or nNOS inhibitors (L-NAME or SMTC, respectively). Experiments were performed under different O concentrations (0-21%). Key findings were: (i) eNOS-derived NO inhibits angiogenic growth by a mechanism independent on sGC pathway and related to inhibition of mitochondrial O consumption; (ii) NO inhibition of the angiogenic growth is more evident in hypoxic vessels; (iii) in the absence of eNOS-derived NO, the modulation of angiogenic growth, related to hypoxia, disappears. Therefore, NO, but not lower O levels, decreases the angiogenic response in hypoxia through competitive inhibition of CcO. This anti-angiogenic activity could be a promising target to impair pathological angiogenesis in hypoxic conditions, as it occurs in tumors or ischemic diseases.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mitochondrial Dysfunction and Mitophagy in Type 2 Diabetes: Pathophysiology and Therapeutic Targets

  • Apostolova, Nadezda
  • Vezza, Teresa
  • Muntané, Jordi
  • Rocha, Milagros
  • Victor, Víctor M.
Significance: Type 2 diabetes mellitus, which is related to oxidative stress and mitochondrial dysfunction, is one of the most prevalent diseases in the world. In the past decade, alterations in autophagy have been shown to play a fundamental role in the development and control of type 2 diabetes. Further, mitophagy has been recognized as a key player in eliminating dysfunctional mitochondria in this disease. Recent Advances: Recently, much progress has been made in understanding the molecular events associated with oxidative stress, mitochondrial dysfunction, and alterations in autophagy and mitophagy in type 2 diabetes. Critical Issues: Despite increasing evidence of a relationship between mitochondrial dysfunction, oxidative stress, and alterations of autophagy and mitophagy and their role in the pathophysiolology of type 2 diabetes, effective therapeutic strategies to combat the disease through targeting mitochondria, autophagy, and mitophagy are yet to be implemented. Future Directions: This review provides a wide perspective of the existing literature concerning the complicated interplay between autophagy, mitophagy, and mitochondrial dysfunction in type 2 diabetes. Further, potential therapeutic targets based on these molecular mechanisms are explored. Antioxid. Redox Signal. 39, 278–320., This research was supported by the European Regional Development Fund (ERDF “A way to build Europe”); FISABIO (Foundation for the Promotion of Health and Biomedical Research in the Valencian Region, grants UGP15-220 and UGP-21-236); Generalitat Valenciana (grants PROMETEO/2019/027 and AICO/2021/017); and Spanish Ministry of Science and Innovation (grants CIBERehd CB06/04/0071, PI22/00424, PI22/1009, PI19/0437, and PI19/00838 from Carlos III Health Institute, and grant PID2021-127945OB-I00 funded by MCIN/AEI/10.13.039/501100011033/and by FEDER)., Peer reviewed